R&D Sustainability of Biotech Start-ups in Financial Risk

다국어 초록 (Multilingual Abstract)

This paper's objective is to draw a decision guideline to continue research and development (R&D) investments in biotech start-ups facing the "Valley of Death" syndrome - a long negative profit period during a financial crisis. The data include financial indices as Net income, Revenues, Total stockholders' equity, Cash & equivalents, and R&D expenses of 18 major biotech companies (nine in negative profit and nine positive, in FY2008) and 15 major pharmaceutical corporations as benchmarks both in FY2008 and in FY2016 derived from the US SEC Database, EDGAR. A first methodology dealing with real options analysis assumes Total stockholders' equity as a growth option. And a second methodology, Bayesian Markov chain Monte Carlo (MCMC) analysis, is applied to test the probability relationship between the Total stockholders' equity and the R&D expenses in these three groups. This study confirms that Total stockholders' equity can play the role of a call option to support continuing R&D investments even in negative profits.

참고문헌 (Reference)

1 Zhong, H., "Which startup to invest in: a personalized portfolio strategy" 263 (263): 339-360, 2018

2 Ottoo, R.E., "Valuation of internal growth opportunities: the case of a biotechnology company" 38 (38): 615-633, 1998

3 Bogdan, B., "Valuation in Life Sciences: A Oractical Guide" Springer 2010

4 Auerswald, P. E., "Valleys of death and darwinian seas: financing the invention to innovation transition in the united states" 28 (28): 227-239, 2003

5 Kester, W.C., "Today’s options for tomorrow’s growth" 62 (62): 153-160, 1984

6 Merton, R.C., "Theory of rational option pricing" 4 (4): 141-183, 2007

7 Black, F., "The pricing of options and corporate liabilities" 81 (81): 637-659, 1973

8 Etzkowitz, H., "The new visible hand: an assisted linear model of science and innovation policy" 33 (33): 310-320, 2006

9 Feldman, M. P., "The locational dynamics of the US biotech industry: knowledge externalities and the anchor hypothesis" 10 (10): 311-328, 2003

10 Werth, B., "The Antidote: Inside the World of New Pharma" Simon & Schuster 2014

11 Block, F., "Swimming against the current: the rise of a hidden developmental state in the united states" 36 (36): 169-206, 2008

12 Teconomy Partners LLC, "Strengthening Biopharmaceutical Innovation" PhRMA 2018

13 Amram, M., "Strategy and shareholder value creation: the real options frontier" 13 (13): 15-28, 2000

14 Audretsch, D. B., "Social capital building and new business formation: a case study in silicon valley" 29 (29): 152-169, 2011

15 Jägle, A.J., "Shareholder value, real options, and innovation in technology-intensive companies" 29 (29): 271-288, 1999

16 Binder, G., "Science Lessons: What the Business of Biotech Taught Me about Management" Harvard Business School Press 2008

17 Pisano, G. P., "Science Business: The Promise, the Reality and the Future of Biotech" Harvard Business School Press 2006

18 Brindley, D., "Regenerative medicine through a crisis: social perception and the financial reality" 12 (12): 455-461, 2009

19 Perlitz, M., "Real options valuation: the new frontier in R&D project evaluation?" 29 (29): 255-270, 1999

20 Bowman, E.H., "Real options analysis and strategic decision making" 12 (12): 772-777, 2001

21 Copeland, T. E., "Real Options" Texere 2001

22 Moran, N., "Public sector seeks to bridge 'valley of death'" 25 (25): 266-, 2007

23 Vassolo, R. S., "Non-additivity in portfolios of exploration activities: a real options-based analysis of equity alliances in biotechnology" 25 (25): 1045-1061, 2004

24 Dixit, A., "Investment Under Uncertainty" Princeton University Press 1994

25 Hughes, S. S., "Genentech: The Beginnings of Biotech (Synthesis)" University of Chicago Press 2011

26 Garnsey, E.W, "Flexibility and specialization in question; birth, growth and death rates of Cambridge new technology-based firms 1988-92" 6 (6): 81-107, 2006

27 McGrath, R. G., "Falling forward: real options reasoning and entrepreneurial failure" 24 (24): 13-30, 1999

28 Aktekin, T., "Entrepreneurial firms and financial attractiveness for securing debt capital: a Bayesian analysis" 20 (20): 1-24, 2017

29 USA Securities and Exchange Commission, "EDGAR"

30 Kruschke, J., "Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan" Academic Press 2014

31 Castellaneta, F., "Does ownership matter in private equity? the sources of variance in buyouts' performance" 37 (37): 330-348, 2014

32 Myers, S.C., "Determinants of corporate borrowing" 5 (5): 147-176, 1977

33 Finkbeiner, S., "Bridging the valley of death of therapeutics for neurode-generation" 16 : 1227-1232, 2010

34 Audretsch, B., "Agglomeration and the location of innovative activity" 14 (14): 18-29, 1998

35 Waluszewski, A., "A competing or co-operating cluster or seven decades of combinatory resources? what's behind a prospering biotech valley?" 20 (20): 125-150, 2004